SCHEMBL2010199

SCHEMBL2010199

COc1ccc(-c2ccc(C=O)cc2)cc1F

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 1/20 0.60
CYP17A1 P05093 1/20 0.55
ALDH1A1 P00352 8/20 0.55
TSHR P16473 1/20 0.55
KIF11 P52732 1/20 0.54
TUBB1 Q9H4B7 3/20 0.51
HPGD P15428 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
POLB P06746 1/20 0.50
AOX1 Q06278 1/20 0.50
TDP2 O95551 1/20 0.49
FDPS P14324 1/20 0.47
PTGS2 P35354 2/20 0.47
PDGFRB P09619 1/20 0.47
PDGFRA P16234 1/20 0.47
TRIM24 O15164 1/20 0.46
ALDH5A1 P51649 1/20 0.46
ABAT P80404 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL435689 0.85 ALDH1A1 (0.68) ERN1ALDH1A1TSHRTUBB1HPGD
SCHEMBL29400600 0.85 ALDH1A1 (0.68) ERN1ALDH1A1TSHRTUBB1HPGD
SCHEMBL7531959 0.85 ALDH1A1 (0.68) ERN1ALDH1A1TSHRTUBB1HPGD
SCHEMBL7218179 0.84 ALDH1A1 (0.71) ERN1ALDH1A1TSHRTUBB1HPGD
SCHEMBL23904949 0.83 ERN1 (0.50) ERN1ALDH1A1TSHRKIF11TUBB1
SCHEMBL9464193 0.83 CYP17A1 (0.61) ERN1CYP17A1ALDH1A1TUBB1MEN1
SCHEMBL14610546 0.82 TUBB1 (0.52) ERN1ALDH1A1TSHRTUBB1HPGD
SCHEMBL18640078 0.81 ALDH1A1 (0.56) ERN1ALDH1A1TSHRHPGDAOX1
SCHEMBL15605813 0.80 CYP17A1 (0.58) ERN1CYP17A1ALDH1A1TUBB1MEN1
SCHEMBL3972458 0.79 ALDH1A1 (0.55) ERN1ALDH1A1TSHRTUBB1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120295915-A1 AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC 2012-11-22 US disclosed
EP-2503890-A1 AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS GlaxoSmithKline LLC (US) 2012-10-03 EP disclosed
WO-2011066211-A1 AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-06-03 WO disclosed
US-20070003735-A1 Display device FUJI PHOTO FILM CO., LTD. (JP) 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295915-A1 AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS FASN, FADS1, COASY ERN1 2424/4885CYP17A1 484/4885ALDH1A1 187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.